#gamida

Israeli Gamida Cell raises $50m in Nasdaq IPO

Israeli cellular and immune therapeutics company Gamida Cell (GMDA) completed its IPO on Nasdaq, Globes reports.

The company set out to raise $ 50-60 million at a valuation of $ 275 million before the money. In the event, it raised $ 50 million, but at a lower valuation – $ 165 million before the money. The company offered an upsized 6.25 million shares, 75% more shares than expected, at $ 8,…

Novartis to invest in $60m Israeli Gamida Cell Nasdaq IPO

The Israeli stem cell cancer therapy developer will hold the offering at a company valuation of $ 275 million, Globes reports.

Israeli stem cell cancer therapy developer Gamida Cell Ltd. has filed a revised public registration statement with the US Securities and Exchange Commission (SEC) to raise $ 50-60 million on Nasdaq at a company valuation of $ 275 million "before money." Gamida Cell said…